Enliven Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Enliven Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ELVN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001672619
Board of directors
-
Andrew J. Schwab · DirectorSince 2023
-
Andrew John Phillips · DirectorSince 2023
-
Helen Louise Collins · DirectorSince 2023
-
J. Scott Garland · DirectorSince 2026
-
Jake Bauer · DirectorSince 2023
-
Joseph P. Lyssikatos · Director · CHIEF SCIENTIFIC OFFICERSince 2023
-
Lori Anne Kunkel · DirectorSince 2024
-
Mika K. Derynck · DirectorSince 2023
-
Rahul D. Ballal · DirectorSince 2023
-
Richard A. Fair · Director · PRESIDENT AND CEOSince 2025
-
Richard A. Heyman · DirectorSince 2023
-
Rishi Gupta · DirectorSince 2023
-
Samuel Kintz · Director · PRESIDENT AND CEOSince 2023
Chief executives
Richard A. Fair
· PRESIDENT AND CEO
Since December 2025
Samuel Kintz
· President and CEO
Until December 2025
· Former
Board connections
8 of this board's directors also sit on 14 other boards.
- via Lori Anne Kunkel and Richard A. Heyman
- via J. Scott Garland
- via Rahul D. Ballal
- via Jake Bauer
- via Andrew J. Schwab
- via Jake Bauer
- via Helen Louise Collins
- via J. Scott Garland
- via Andrew John Phillips
- via Lori Anne Kunkel
- via J. Scott Garland
- via Andrew John Phillips
- via Richard A. Heyman
- via Andrew J. Schwab
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $76,570,014
- 77 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Option exercise | +5,000 | $2.48 | $12,400 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Option exercise | +3,982 | $14.85 | $59,133 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −2,916 | $50.03 | $145,891 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −3,535 | $50.03 | $176,851 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,844 | $50.71 | $93,507 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −2,194 | $50.72 | $111,270 |
| Sep 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −240 | $51.48 | $12,356 |
| Sep 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −289 | $51.49 | $14,881 |
| Aug 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Option exercise | +5,000 | $2.48 | $12,400 |
| Aug 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −4,630 | $58.35 | $270,168 |
| Aug 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −3,900 | $58.37 | $227,650 |
| Aug 17, 2026 | Hohl Benjamin Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | −1,388 | $59.35 | $82,383 |
| Aug 17, 2026 | Helen Louise Collins Officer (CHIEF MEDICAL OFFICER) | Open-market sale | −1,100 | $59.35 | $65,281 |
| Aug 4, 2026 | Mika K. Derynck Director | Option exercise | +87,373 | $2.48 | $216,685 |
| Aug 4, 2026 | Mika K. Derynck Director | Option exercise | +27,567 | $25.28 | $696,894 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.